---
layout: default
title: Prednisolone Acetate
parent: Model Prediction Only (L5)
nav_order: 759
evidence_level: L5
indication_count: 10
---

# Prednisolone Acetate
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Prednisolone Acetate: From Topical Anti-Inflammatory Corticosteroid Use to Conjunctival Folliculosis

## One-Sentence Summary

Prednisolone acetate is a topical glucocorticoid with broad anti-inflammatory action, and it is marketed in Canada under three DINs.
The TxGNN model predicts it may be effective for **conjunctival folliculosis**, but **no clinical trials and no publications** were retrieved for this specific indication, so the prediction rests on the model score alone.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not specified in the available regulatory data |
| Predicted New Indication | Conjunctival folliculosis |
| TxGNN Prediction Score | 99.74% |
| Evidence Level | L5 (model prediction only) |
| Canada Market Status | ✓ Marketed |
| Number of DINs | 3 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Prednisolone acetate is a topical glucocorticoid, and glucocorticoids broadly suppress inflammatory and immune-mediated responses. Mechanistically, it could be applicable to inflammatory conjunctival conditions.

The link to conjunctival folliculosis is weak. Folliculosis is usually benign and often non-inflammatory, so there may be little inflammation for a corticosteroid to treat. The high model score (99.74%) should be read as a statistical association in the knowledge graph, not as evidence of benefit.

For context, the same drug has more plausible links to related conjunctival diseases. Examples are vernal conjunctivitis and papillary conjunctivitis, which are driven by mast cells and Th2 inflammation. Those candidates are covered briefly in the conclusion.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Canada Market Information

| DIN | Product Name | Dosage Form | Approved Indication |
|---------|------|------|-----------|
| 1916203 | SANDOZ PREDNISOLONE | Not listed | Not listed |
| 301175 | PRED FORTE | Not listed | Not listed |
| 700401 | TEVA-PREDNISOLONE | Not listed | Not listed |

---

## Safety Considerations

Please refer to the package insert for safety information. No drug interaction records were found.

Class-level cautions from the retrieved literature on topical ophthalmic corticosteroids:
- Prolonged use carries a risk of raised intraocular pressure, glaucoma and cataract.
- Steroids are not appropriate for infectious causes of conjunctivitis unless the pathogen is also treated. Viral and parasitic causes are examples.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction has the lowest evidence level (L5), with no trials or literature for conjunctival folliculosis. The condition is often non-inflammatory, so the mechanistic fit is weak. The package insert safety review is also incomplete.

**Other predicted indications:** Vernal conjunctivitis (score 99.58%) and papillary conjunctivitis (99.72%) have a stronger mechanistic fit and are rated L4 (Research Question). Their evidence is mostly about other agents (cyclosporine, loteprednol) and corticosteroid IOP safety. It does not include a controlled evaluation of prednisolone acetate. They would be better starting points than folliculosis.

**To proceed, the following is needed:**
- Health Canada package insert warnings and contraindications (a blocking gap for safety screening)
- Mechanism of action data, for example from DrugBank
- Approved indications and dosage forms for the three DINs
- A direct clinical or observational study of prednisolone acetate in the target condition
- A case definition that separates inflammatory from non-inflammatory folliculosis, and rules out infectious causes
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

